$ADPT Adaptive Biotechnologies Corp Insider Trading Week 20/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Adaptive Biotechnologies Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Adaptive Biotechnologies Corp in week 20/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 50,000 | 16,500 | 451,560 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 50,000 | 16,500 | 501,560 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 50,000 | 16,500 | 551,560 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Gift | G | 0.00 | 100,000 | 0 | 1,778,180 | 1.9 M to 1.8 M (-5.32 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 40.29 | 50,000 | 2,014,500 | 1,878,180 | 1.9 M to 1.9 M (-2.59 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 50,000 | 16,500 | 1,928,180 | 1.9 M to 1.9 M (+2.66 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 40.46 | 50,000 | 2,023,000 | 1,878,180 | 1.9 M to 1.9 M (-2.59 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 50,000 | 16,500 | 1,928,180 | 1.9 M to 1.9 M (+2.66 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 39.95 | 49,100 | 1,961,545 | 1,878,180 | 1.9 M to 1.9 M (-2.55 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 39.31 | 900 | 35,379 | 1,927,280 | 1.9 M to 1.9 M (-0.05 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 50,000 | 16,500 | 1,928,180 | 1.9 M to 1.9 M (+2.66 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 7.27 | 25,000 | 181,750 | 50,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 49,479 | 324,087 | 75,521 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 78,125 | 511,719 | 45,875 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.27 | 15,416 | 96,658 | 4,584 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 50,000 | 16,500 | 451,560 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.32 | 18,750 | 118,500 | 1,250 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 50,000 | 16,500 | 501,560 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 1.98 | 60,000 | 118,800 | 0 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Option Exercise | M | 0.33 | 50,000 | 16,500 | 551,560 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 40.00 | 246,770 | 9,870,800 | 0 | 246.8 K to 0 (-100.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Gift | G | 0.00 | 100,000 | 0 | 1,778,180 | 1.9 M to 1.8 M (-5.32 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 7.27 | 25,000 | 181,750 | 246,770 | 221.8 K to 246.8 K (+11.27 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 40.29 | 50,000 | 2,014,500 | 1,878,180 | 1.9 M to 1.9 M (-2.59 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 49,479 | 324,087 | 221,770 | 172.3 K to 221.8 K (+28.72 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 50,000 | 16,500 | 1,928,180 | 1.9 M to 1.9 M (+2.66 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 78,125 | 511,719 | 172,291 | 94.2 K to 172.3 K (+82.97 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 40.46 | 50,000 | 2,023,000 | 1,878,180 | 1.9 M to 1.9 M (-2.59 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.27 | 15,416 | 96,658 | 94,166 | 78.8 K to 94.2 K (+19.58 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 50,000 | 16,500 | 1,928,180 | 1.9 M to 1.9 M (+2.66 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.32 | 18,750 | 118,500 | 78,750 | 60 K to 78.8 K (+31.25 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 39.95 | 49,100 | 1,961,545 | 1,878,180 | 1.9 M to 1.9 M (-2.55 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 1.98 | 60,000 | 118,800 | 60,000 | 0 to 60 K |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Sell | S | 39.31 | 900 | 35,379 | 1,927,280 | 1.9 M to 1.9 M (-0.05 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.48 | 31,372 | 1,269,939 | 679 | 32.1 K to 679 (-97.88 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS CHAD M | CEO and Chairman | Buy | M | 0.33 | 50,000 | 16,500 | 1,928,180 | 1.9 M to 1.9 M (+2.66 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.11 | 38,628 | 1,549,369 | 32,051 | 70.7 K to 32.1 K (-54.65 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 7.27 | 25,000 | 181,750 | 50,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 4.07 | 30,000 | 122,100 | 0 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 49,479 | 324,087 | 75,521 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 20,000 | 126,400 | 700,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.55 | 78,125 | 511,719 | 45,875 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.00 | 50,000 | 2,000,000 | 1,000 | 51 K to 1,000 (-98.04 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.27 | 15,416 | 96,658 | 4,584 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 20,000 | 126,400 | 51,000 | 31 K to 51 K (+64.52 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 6.32 | 18,750 | 118,500 | 1,250 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 4.07 | 30,000 | 122,100 | 31,000 | 1,000 to 31 K (+3,000.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Option Exercise | M | 1.98 | 60,000 | 118,800 | 0 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 5,000 | 31,600 | 70,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Sell | S | 40.00 | 246,770 | 9,870,800 | 0 | 246.8 K to 0 (-100.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 40.00 | 5,000 | 200,000 | 0 | 5 K to 0 (-100.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 7.27 | 25,000 | 181,750 | 246,770 | 221.8 K to 246.8 K (+11.27 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 5,000 | 31,600 | 5,000 | 0 to 5 K |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 49,479 | 324,087 | 221,770 | 172.3 K to 221.8 K (+28.72 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.55 | 78,125 | 511,719 | 172,291 | 94.2 K to 172.3 K (+82.97 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.27 | 15,416 | 96,658 | 94,166 | 78.8 K to 94.2 K (+19.58 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 6.32 | 18,750 | 118,500 | 78,750 | 60 K to 78.8 K (+31.25 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | BENZENO SHARON | Chief Business Deve ... | Buy | M | 1.98 | 60,000 | 118,800 | 60,000 | 0 to 60 K |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.48 | 31,372 | 1,269,939 | 679 | 32.1 K to 679 (-97.88 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 40.11 | 38,628 | 1,549,369 | 32,051 | 70.7 K to 32.1 K (-54.65 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 4.07 | 30,000 | 122,100 | 0 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Option Exercise | M | 6.32 | 20,000 | 126,400 | 700,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Sell | S | 40.00 | 50,000 | 2,000,000 | 1,000 | 51 K to 1,000 (-98.04 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 6.32 | 20,000 | 126,400 | 51,000 | 31 K to 51 K (+64.52 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | Cohen Chad M | Chief Financial Off ... | Buy | M | 4.07 | 30,000 | 122,100 | 31,000 | 1,000 to 31 K (+3,000.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Option Exercise | M | 6.32 | 5,000 | 31,600 | 70,000 | |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Sell | S | 40.00 | 5,000 | 200,000 | 0 | 5 K to 0 (-100.00 %) |
| May 21 2020 | ADPT | Adaptive Biotechno ... | DOBMEIER ERIC | Director | Buy | M | 6.32 | 5,000 | 31,600 | 5,000 | 0 to 5 K |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 73,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 36.10 | 398 | 14,368 | 0 | 398 to 0 (-100.00 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Option Exercise | M | 0.45 | 2,000 | 900 | 73,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 35.23 | 400 | 14,092 | 398 | 798 to 398 (-50.13 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 36.10 | 398 | 14,368 | 0 | 398 to 0 (-100.00 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 34.14 | 1,202 | 41,036 | 798 | 2 K to 798 (-60.10 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 35.23 | 400 | 14,092 | 398 | 798 to 398 (-50.13 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Sell | S | 34.14 | 1,202 | 41,036 | 798 | 2 K to 798 (-60.10 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 433,500 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | HERSHBERG ROBERT | Director | Buy | M | 0.45 | 2,000 | 900 | 2,000 | 0 to 2 K |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 35,400 | 223,728 | 444,600 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 11,100 | 70,152 | 433,500 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 31,200 | 197,184 | 480,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 35,400 | 223,728 | 444,600 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.36 | 10,500 | 413,280 | 70,679 | 81.2 K to 70.7 K (-12.93 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Option Exercise | M | 6.32 | 31,200 | 197,184 | 480,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.67 | 600 | 23,202 | 81,179 | 81.8 K to 81.2 K (-0.73 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 39.36 | 10,500 | 413,280 | 70,679 | 81.2 K to 70.7 K (-12.93 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 81,779 | 70.7 K to 81.8 K (+15.70 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.67 | 600 | 23,202 | 81,179 | 81.8 K to 81.2 K (-0.73 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.11 | 7,158 | 272,791 | 70,679 | 77.8 K to 70.7 K (-9.20 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 11,100 | 70,152 | 81,779 | 70.7 K to 81.8 K (+15.70 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 37.53 | 22,342 | 838,495 | 77,837 | 100.2 K to 77.8 K (-22.30 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 38.11 | 7,158 | 272,791 | 70,679 | 77.8 K to 70.7 K (-9.20 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 36.34 | 5,400 | 196,236 | 100,179 | 105.6 K to 100.2 K (-5.11 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 37.53 | 22,342 | 838,495 | 77,837 | 100.2 K to 77.8 K (-22.30 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 35.13 | 400 | 14,052 | 105,579 | 106 K to 105.6 K (-0.38 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 36.34 | 5,400 | 196,236 | 100,179 | 105.6 K to 100.2 K (-5.11 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 33.56 | 100 | 3,356 | 105,979 | 106.1 K to 106 K (-0.09 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 35.13 | 400 | 14,052 | 105,579 | 106 K to 105.6 K (-0.38 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 33.56 | 100 | 3,356 | 105,979 | 106.1 K to 106 K (-0.09 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 35,400 | 223,728 | 106,079 | 70.7 K to 106.1 K (+50.09 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 35,400 | 223,728 | 106,079 | 70.7 K to 106.1 K (+50.09 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 35.44 | 28,000 | 992,320 | 70,679 | 98.7 K to 70.7 K (-28.37 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 35.44 | 28,000 | 992,320 | 70,679 | 98.7 K to 70.7 K (-28.37 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 34.26 | 3,200 | 109,632 | 98,679 | 101.9 K to 98.7 K (-3.14 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Sell | S | 34.26 | 3,200 | 109,632 | 98,679 | 101.9 K to 98.7 K (-3.14 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 31,200 | 197,184 | 101,879 | 70.7 K to 101.9 K (+44.14 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | ROBINS HARLAN S | Chief Scientific Of ... | Buy | M | 6.32 | 31,200 | 197,184 | 101,879 | 70.7 K to 101.9 K (+44.14 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Option Exercise | M | 6.55 | 20,000 | 131,000 | 230,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Option Exercise | M | 6.55 | 20,000 | 131,000 | 230,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Option Exercise | M | 6.32 | 20,000 | 126,400 | 80,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Option Exercise | M | 6.32 | 20,000 | 126,400 | 80,000 | |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Sell | S | 38.01 | 40,000 | 1,520,400 | 0 | 40 K to 0 (-100.00 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Sell | S | 38.01 | 40,000 | 1,520,400 | 0 | 40 K to 0 (-100.00 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Buy | M | 6.55 | 20,000 | 131,000 | 40,000 | 20 K to 40 K (+100.00 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Buy | M | 6.55 | 20,000 | 131,000 | 40,000 | 20 K to 40 K (+100.00 %) |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Buy | M | 6.32 | 20,000 | 126,400 | 20,000 | 0 to 20 K |
| May 18 2020 | ADPT | Adaptive Biotechno ... | SANG CHARLES | SVP, Clinical Diagn ... | Buy | M | 6.32 | 20,000 | 126,400 | 20,000 | 0 to 20 K |